Towards Healthcare

Non-Invasive Prenatal Testing Companies and Development Strategy

Date : 01 October 2025

Top Companies in the Market

Non-Invasive Prenatal Testing Market Companies

Market Growth

The non-invasive prenatal testing market size is calculated at US$ 6.45 billion in 2024, grew to US$ 7.2 billion in 2025, and is projected to reach around US$ 18.94 billion by 2034. The market is expanding at a CAGR of 11.65% between 2025 and 2034.

  • Technological Advancements: Next-generation sequencing and bioinformatics advancements have significantly enhanced NIPT's precision, speed, and scope. Through the examination of cell-free fetal DNA in maternal blood samples, these advancements enable the identification of a broader range of genetic disorders, including rare chromosomal abnormalities. As a result of ongoing research, NIPT is becoming increasingly available, with faster turnaround times and more affordable testing solutions.
  • In September 2024, Illumina launched DRAGEN v4.3, its next-generation sequencing software, enhancing the efficiency and accuracy of NIPT analyses.
  • Portfolio Diversification by Companies: In addition to trisomy, companies are now offering NIPTs for microdeletions, sex chromosome aneuploidies, and single-gene disorders. As a result, providers can now offer complete screening solutions, boosting market competition. For focused screening, providers are also launching test panels that can be customized. Hospitals and clinics looking for specialized prenatal diagnostics are drawn to this flexibility.
  • In 14, 2025, LabCorp launched an expanded NIPT panel covering additional genetic conditions. The new panel allows providers to detect rare genetic disorders, making LabCorp a more comprehensive choice for hospitals and prenatal clinics.

Value Chain Analysis

R&D

R&D aims to increase test sensitivity, lower costs, and broaden the range of genetic conditions that can be detected in the non-invasive prenatal testing market. The development of next-generation sequencing, powered data interpretation, and innovations in liquid biopsy to improve diagnostic precision are important areas of focus. Additionally, research is focusing on single-gene disorders and the detection of uncommon microdeletions.

Key Players: Natera, Roche, BGI Genomics, and Invitae.

Clinical Trials & Regulatory Approvals

To guarantee safety, accuracy, and ethical compliance, noninvasive prenatal testing is subject to strict regulatory oversight, authorization from the FDA (U.S.A.), and the commercialization of advanced screening platforms depends on CE (Europe) and CDSCO. Clinical trials are essential for confirming accuracy in a variety of populations, especially when it comes to rare genetic abnormalities and early trimester testing.

Key Players: Natera, Illumina, Roche, Labcorp, and BGI Genomics are actively engaged in regulatory-compliant solutions and expanding trial evidence to support broader clinical adoption.

Patient Support & Services

Patient support in the NIPT market prioritizes ease of access, early detection, and result confidence. To enhance teleconsultations, home sample collection and quick digital reporting are becoming commonplace services. Convenience is also being improved by integration with hospital and clinic systems and educational outreach to raise awareness among expectant parents.

Key Players: Natera, Labcorp, Roche, Quest Diagnostics, and MedGenome.

Latest Announcements by Industry Leaders

In May 2025, BillionToOne, Inc. launches an expanded panel for UNITY Fetal Risk Screen. Oguzhan Atay, Ph.D., Co-founder and CEO of BillionToOne, said: “By expanding our products to include a 14-gene offering that includes these prevalent and actionable conditions, we’re providing healthcare providers and expectant parents with vital information that can significantly impact pregnancy management and long-term health outcomes.”

Recent Developments

  • In June 2025, BGI Genomics and Prom-Test Laboratories launched the first localized NIPT project in Armenia using the NIFTY test, after a technology transfer, to make prenatal screening more accessible locally.
  • In January 2025, Myriad Genetics revealed study results showing its Prequel Prenatal Screen with AMPLIFY technology enables accurate cfDNA screening as early as eight weeks of gestation

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com